Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists. - Wikidata - awgldk - TriplyDB

Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.

Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.

http://www.wikidata.org/entity/Q37859364

about

PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation.Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.Challenges for HCV vaccine development in HIV-HCV coinfection.Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.

P2860

Q34074331-B9C0B42B-50C1-4394-9A2B-45DAA98E1202 Q34359120-73C10331-437F-4D5B-8BB5-105AD90E75EE Q35866994-C58AFC79-9024-4DAD-8E26-E3B5A28FE0C6 Q36698602-C8ACCE9F-DFDB-4B02-85CA-EDAD85E712CD Q38036684-737C26C8-C5DB-43F5-BA8A-CC7CBDDFB16E Q38066535-3025E5E3-2C5C-4DB4-8C7B-BB49D9B8E435 Q44369266-1A2A1C37-690F-4979-9CA8-B673F0FE2253

P2860

Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.

http://www.wikidata.org/entity/Q37859364

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Coinfection with human immunod ...... fectious Diseases Pharmacists.

@en

Coinfection with human immunod ...... fectious Diseases Pharmacists.

@nl

type

label

Coinfection with human immunod ...... fectious Diseases Pharmacists.

@en

Coinfection with human immunod ...... fectious Diseases Pharmacists.

@nl

prefLabel

Coinfection with human immunod ...... fectious Diseases Pharmacists.

@en

Coinfection with human immunod ...... fectious Diseases Pharmacists.

@nl

P1433

Q37859364-0EB5A05C-FAFB-4353-B58C-F1FA25436E82

P1476

Q37859364-3957B423-73C9-424E-A1CB-B74F01C9669F

P2093

Q37859364-5DE07AF3-F42F-49F5-BC42-C4599A730901

Q37859364-EAD72E52-B74E-4C53-BF80-E201008F1C43

P2860

Q37859364-0315D36B-F79E-4DA2-A9FA-94EFCB879C8F

Q37859364-050BB2CF-E174-4815-8FE6-7E2F091287F3

Q37859364-0747285F-5020-4370-9BF3-8BC2953DA979

Q37859364-07A40315-7116-43FA-A1AC-51ECD1940F8F

Q37859364-0F94D515-DA60-4E6F-9897-249066B855FA

Q37859364-18CFCDCD-F944-4ACC-9CFD-42AACD20164D

Q37859364-1975B81D-E95E-4D65-9026-3897883CE0E7

Q37859364-1F543BCE-A061-4116-85AE-B79613775C44

Q37859364-27355753-899E-4AC2-BD0C-95417DC84823

Q37859364-3107EF64-771A-4EF7-8B75-B9FB76970AF1

P304

Q37859364-E46A873F-0D1C-461B-8AA3-3CFE4BDE45B5

P31

Q37859364-DE6A1281-541F-4DAB-AC6A-D175009D3F61

P356

Q37859364-37497938-554F-4EA7-B635-F0ADCBAA49B4

P407

Q37859364-F8DB2888-3355-4C4F-9654-215992661875

P433

Q37859364-15739D8B-3526-4348-9DB3-CC3F65CE8135

P478

Q37859364-E18CE13C-23F8-4346-B020-EB082C4F73EF

P50

Q37859364-AC1B361E-ADC1-4460-8189-68274A605BEF

P577

Q37859364-6E740EBF-AE31-4106-A239-5DECACD76994

P698

Q37859364-ABF79008-82E9-4F00-8BD4-687BD4202DD9

P356

P1433

Pharmacotherapy

P1476

Coinfection with human immunod ...... fectious Diseases Pharmacists.

@en

P2093

Ian R McNicholl

http://www.w3.org/2001/XMLSchema#string

Paulina Deming

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

Diagnosis, management, and treatment of hepatitis C: an update

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.

Side effects of therapy of hepatitis C and their management.

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.

Viral hepatitis and HIV coinfection.

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.

Boceprevir, an NS3 protease inhibitor of HCV.

P304

357-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.31.4.357

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21449625

http://www.w3.org/2001/XMLSchema#string